Literature DB >> 24312699

Analogs of the Allosteric Heat Shock Protein 70 (Hsp70) Inhibitor, MKT-077, as Anti-Cancer Agents.

Xiaokai Li1, Sharan R Srinivasan, Jamie Connarn, Atta Ahmad, Zapporah T Young, Adam M Kabza, Erik R P Zuiderweg, Duxin Sun, Jason E Gestwicki.   

Abstract

The rhodacyanine, MKT-077, has anti-proliferative activity against cancer cell lines through its ability to inhibit members of the heat shock protein 70 (Hsp70) family of molecular chaperones. However, MKT-077 is rapidly metabolized, which limits its use as either a chemical probe or potential therapeutic. We report the synthesis and characterization of MKT-077 analogs designed for greater stability. The most potent molecules, such as 30 (JG-98), were at least 3-fold more active than MKT-077 against the breast cancer cell lines MDA-MB-231 and MCF-7 (EC50 values of 0.4 ± 0.03 μM and 0.7 ± 0.2 μM, respectively). The analogs modestly destabilized the chaperone "clients", Akt1 and Raf1, and induced apoptosis in these cells. Further, the microsomal half-life of JG-98 was improved at least 7-fold (t1/2 = 37 min) compared to MKT-077 (t1/2 < 5 min). Finally, NMR titration experiments suggested that these analogs bind an allosteric site that is known to accommodate MKT-077. These studies advance MKT-077 analogs as chemical probes for studying Hsp70's roles in cancer.

Entities:  

Keywords:  Hsp90; breast cancer; mortalin; p53; proteostasis

Year:  2013        PMID: 24312699      PMCID: PMC3845967          DOI: 10.1021/ml400204n

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  28 in total

Review 1.  Inhibition of HSP70: a challenging anti-cancer strategy.

Authors:  Anastasia R Goloudina; Oleg N Demidov; Carmen Garrido
Journal:  Cancer Lett       Date:  2012-06-28       Impact factor: 8.679

2.  Allosteric drugs: the interaction of antitumor compound MKT-077 with human Hsp70 chaperones.

Authors:  Aikaterini Rousaki; Yoshinari Miyata; Umesh K Jinwal; Chad A Dickey; Jason E Gestwicki; Erik R P Zuiderweg
Journal:  J Mol Biol       Date:  2011-06-25       Impact factor: 5.469

3.  Induction of heat shock protein 70 (Hsp70) by proteasome inhibitor MG 132 protects articular chondrocytes from cellular death in vitro and in vivo.

Authors:  Laurent Grossin; Stéphanie Etienne; Nadège Gaborit; Astrid Pinzano; Christel Cournil-Henrionnet; Catherine Gerard; Elisabeth Payan; Patrick Netter; Bernard Terlain; Pierre Gillet
Journal:  Biorheology       Date:  2004       Impact factor: 1.875

4.  MKT-077, a novel rhodacyanine dye in clinical trials, exhibits anticarcinoma activity in preclinical studies based on selective mitochondrial accumulation.

Authors:  K Koya; Y Li; H Wang; T Ukai; N Tatsuta; M Kawakami; L B Chen
Journal:  Cancer Res       Date:  1996-02-01       Impact factor: 12.701

5.  MKT-077, localized lipophilic cation: antitumor activity against human tumor xenografts serially transplanted into nude mice.

Authors:  Y Chiba; T Kubota; M Watanabe; S W Matsuzaki; Y Otani; T Teramoto; Y Matsumoto; K Koya; M Kitajima
Journal:  Anticancer Res       Date:  1998 Mar-Apr       Impact factor: 2.480

6.  Solution conformation of wild-type E. coli Hsp70 (DnaK) chaperone complexed with ADP and substrate.

Authors:  Eric B Bertelsen; Lyra Chang; Jason E Gestwicki; Erik R P Zuiderweg
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-13       Impact factor: 11.205

7.  Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis.

Authors:  Marissa V Powers; Paul A Clarke; Paul Workman
Journal:  Cancer Cell       Date:  2008-09-09       Impact factor: 31.743

8.  A modified HSP70 inhibitor shows broad activity as an anticancer agent.

Authors:  Gregor M Balaburski; Julia I-Ju Leu; Neil Beeharry; Seth Hayik; Mark D Andrake; Gao Zhang; Meenhard Herlyn; Jessie Villanueva; Roland L Dunbrack; Tim Yen; Donna L George; Maureen E Murphy
Journal:  Mol Cancer Res       Date:  2013-01-09       Impact factor: 5.852

9.  Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models.

Authors:  Eloisi Caldas-Lopes; Leandro Cerchietti; James H Ahn; Cristina C Clement; Ana I Robles; Anna Rodina; Kamalika Moulick; Tony Taldone; Alexander Gozman; Yunke Guo; Nian Wu; Elisa de Stanchina; Julie White; Steven S Gross; Yuliang Ma; Lyuba Varticovski; Ari Melnick; Gabriela Chiosis
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-05       Impact factor: 11.205

10.  Rhodacyanine dye MKT-077 inhibits in vitro telomerase assay but has no detectable effects on telomerase activity in vivo.

Authors:  Renu Wadhwa; Lorel Colgin; Tomoko Yaguchi; Kazunari Taira; Roger R Reddel; Sunil C Kaul
Journal:  Cancer Res       Date:  2002-08-01       Impact factor: 12.701

View more
  69 in total

1.  Hsp70:CHIP Ubiquitinates Dysfunctional but Not Native Neuronal NO Synthase.

Authors:  Amanda K Davis; Natalie F McMyn; Miranda Lau; Yoshihiro Morishima; Yoichi Osawa
Journal:  Mol Pharmacol       Date:  2020-06-26       Impact factor: 4.436

2.  Protein Cross-Linking Capillary Electrophoresis for Protein-Protein Interaction Analysis.

Authors:  Claire M Ouimet; Hao Shao; Jennifer N Rauch; Mohamed Dawod; Bryce Nordhues; Chad A Dickey; Jason E Gestwicki; Robert T Kennedy
Journal:  Anal Chem       Date:  2016-07-28       Impact factor: 6.986

Review 3.  The human HSP70 family of chaperones: where do we stand?

Authors:  Jürgen Radons
Journal:  Cell Stress Chaperones       Date:  2016-02-10       Impact factor: 3.667

4.  Exploration of Benzothiazole Rhodacyanines as Allosteric Inhibitors of Protein-Protein Interactions with Heat Shock Protein 70 (Hsp70).

Authors:  Hao Shao; Xiaokai Li; Michael A Moses; Luke A Gilbert; Chakrapani Kalyanaraman; Zapporah T Young; Margarita Chernova; Sara N Journey; Jonathan S Weissman; Byron Hann; Matthew P Jacobson; Len Neckers; Jason E Gestwicki
Journal:  J Med Chem       Date:  2018-07-13       Impact factor: 7.446

Review 5.  Targeting Hsp70 facilitated protein quality control for treatment of polyglutamine diseases.

Authors:  Amanda K Davis; William B Pratt; Andrew P Lieberman; Yoichi Osawa
Journal:  Cell Mol Life Sci       Date:  2019-09-24       Impact factor: 9.261

6.  An RNA polymerase II-driven Ebola virus minigenome system as an advanced tool for antiviral drug screening.

Authors:  Emily V Nelson; Jennifer R Pacheco; Adam J Hume; Tessa N Cressey; Laure R Deflubé; John B Ruedas; John H Connor; Hideki Ebihara; Elke Mühlberger
Journal:  Antiviral Res       Date:  2017-08-12       Impact factor: 5.970

Review 7.  Inhibitors and chemical probes for molecular chaperone networks.

Authors:  Jason E Gestwicki; Hao Shao
Journal:  J Biol Chem       Date:  2018-09-13       Impact factor: 5.157

8.  Validation of the Hsp70-Bag3 protein-protein interaction as a potential therapeutic target in cancer.

Authors:  Xiaokai Li; Teresa Colvin; Jennifer N Rauch; Diego Acosta-Alvear; Martin Kampmann; Bryan Dunyak; Byron Hann; Blake T Aftab; Megan Murnane; Min Cho; Peter Walter; Jonathan S Weissman; Michael Y Sherman; Jason E Gestwicki
Journal:  Mol Cancer Ther       Date:  2015-01-06       Impact factor: 6.261

Review 9.  A model in which heat shock protein 90 targets protein-folding clefts: rationale for a new approach to neuroprotective treatment of protein folding diseases.

Authors:  William B Pratt; Yoshihiro Morishima; Jason E Gestwicki; Andrew P Lieberman; Yoichi Osawa
Journal:  Exp Biol Med (Maywood)       Date:  2014-07-02

Review 10.  Alterations in the E3 ligases Parkin and CHIP result in unique metabolic signaling defects and mitochondrial quality control issues.

Authors:  Britney N Lizama; Amy M Palubinsky; BethAnn McLaughlin
Journal:  Neurochem Int       Date:  2017-08-26       Impact factor: 3.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.